Avelumab and Merkel Cell Carcinoma: Examining Causation

From General Health to Occupational Exposure

The legacy of general health and science information has long provided a foundational framework for understanding disease prevention and wellness. Within this broad context, public health guidance has traditionally emphasized lifestyle factors, environmental exposures, and pharmaceutical interventions as key determinants of health outcomes. This established perspective has shaped how both clinicians and the public evaluate risks associated with medical treatments, including immunotherapies. As the domain of mass production increasingly intersects with healthcare delivery, the focus now shifts from general health principles to specific occupational and therapeutic exposure scenarios. In particular, the administration of Avelumab—a programmed death-ligand 1 blocking antibody used in oncology—raises questions about its potential role in carcinogenesis. While the drug is indicated for certain cancers, the transition from a general health framework to an occupational exposure concern requires careful consideration of how therapeutic agents may inadvertently influence disease risk. This pivot acknowledges that mass production environments, including pharmaceutical manufacturing and clinical administration settings, may present unique exposure pathways. The concern is not merely about general health maintenance but about specific, quantifiable risks associated with Avelumab exposure and the subsequent development of Merkel cell carcinoma. This transition necessitates a neutral examination of exposure-response relationships without invoking mechanistic disease claims.

Avelumab Pharmacology and Clinical Use

Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It functions as an immune checkpoint inhibitor, blocking the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby enhancing the immune system's ability to attack cancer cells. Avelumab has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), making it the first therapeutic agent specifically approved for this indication (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Reported adverse effects of avelumab include immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). These can include conditions such as sarcoidosis, as described in a case report of hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). In that case, hypercalcemia was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). Other irAEs may include dermatitis, colitis, hepatitis, pneumonitis, and endocrinopathies. Despite these risks, immune checkpoint inhibitors like avelumab offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% in metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/).

Merkel Cell Carcinoma: Clinical Presentation and Etiology

Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). It is characterized by rapid growth and a high propensity for metastasis. MCC is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus (https://pubmed.ncbi.nlm.nih.gov/35877101/). The incidence of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Diagnosis typically involves histopathological examination of biopsy specimens, with immunohistochemical staining for neuroendocrine markers such as cytokeratin 20 and synaptophysin. Clinical presentation often includes a rapidly enlarging, painless, firm, red or purple nodule on sun-exposed skin, most commonly on the head, neck, or extremities.

Mechanistic Pathways and Causation Analysis

The query asks whether avelumab causes MCC. The evidence provided does not support a causal relationship in which avelumab induces or initiates the development of MCC. Instead, avelumab is a treatment for MCC, and its mechanism of action involves enhancing the immune response against existing MCC cells. The evidence indicates that avelumab is used to treat metastatic MCC, and it has shown efficacy in inducing objective responses in patients with chemotherapy-refractory disease (https://pubmed.ncbi.nlm.nih.gov/29799096/). Furthermore, for patients who become refractory to avelumab, subsequent treatment with other immune checkpoint inhibitors, such as ipilimumab plus nivolumab, has been explored (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). These studies describe avelumab-refractory MCC, indicating that the disease can progress despite avelumab therapy, but they do not suggest that avelumab causes MCC.

Adequacy of Warnings and Risk Communication

The evidence does not provide specific information on the adequacy of warnings regarding avelumab and MCC. However, given that avelumab is approved for the treatment of MCC, it is reasonable to assume that prescribing information includes warnings about potential adverse effects, including irAEs, and the risk of disease progression. The evidence highlights that approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/), underscoring the need for careful monitoring and management of treatment outcomes.

Causation Considerations for Affected Patients

For patients affected by MCC, the primary causation consideration is the development of the disease itself, which is linked to ultraviolet light exposure and Merkel cell polyoma virus, not to avelumab. Avelumab is a therapeutic agent used to treat MCC, and its use is associated with potential benefits and risks. Patients who experience progression of MCC while on avelumab may be considered avelumab-refractory, and alternative treatment options, such as ipilimumab plus nivolumab, may be considered (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). The evidence does not support a causal link between avelumab and the initiation of MCC.

Timeline Between Exposure and Documented Harm

The evidence does not provide a specific timeline between avelumab exposure and the development of harm in the context of MCC causation. However, in the context of treatment, the JAVELIN Merkel 200 trial demonstrated objective responses in approximately one-third of patients, suggesting that therapeutic effects can be observed within the timeframe of clinical trials (https://pubmed.ncbi.nlm.nih.gov/29799096/). For patients who become refractory to avelumab, the timeline for disease progression is variable and depends on individual patient factors. The evidence from retrospective studies indicates that avelumab-refractory patients may be treated with subsequent therapies, but specific timelines are not detailed (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/).

Conclusion

Based on the provided evidence, avelumab does not cause Merkel cell carcinoma. Instead, it is an approved treatment for metastatic MCC, with demonstrated efficacy in inducing responses in a subset of patients. The evidence supports the role of avelumab as a therapeutic agent, not as a causative factor for MCC. Patients and healthcare providers should be aware of the potential for immune-related adverse events and the possibility of disease progression despite treatment, but there is no evidence to suggest that avelumab initiates or induces MCC.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does Avelumab cause Merkel cell carcinoma?

No, the evidence does not support a causal relationship. Avelumab is an approved treatment for metastatic Merkel cell carcinoma (MCC) and works by enhancing the immune response against existing cancer cells. Studies show it is used to treat MCC, not cause it (https://pubmed.ncbi.nlm.nih.gov/29799096/).

What are the known side effects of Avelumab?

Avelumab can cause immune-related adverse events (irAEs) such as dermatitis, colitis, hepatitis, pneumonitis, endocrinopathies, and reactivation of sarcoidosis (https://pubmed.ncbi.nlm.nih.gov/31543781/). These are due to overactivation of the immune system.

What is the prognosis for Merkel cell carcinoma patients treated with Avelumab?

Approximately one-third of patients with chemotherapy-refractory metastatic MCC achieve objective responses with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, about 50% of patients may progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.